Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study
Gender-affirming hormone therapy is not associated with increased cardiovascular risk in transgender women but is in transgender men. This aligns with known effects of oestradiol and testosterone on cardiovascular risk factors.
Authors
- Chantal M Wiepjes (ORCID: https://orcid.org/0000-0002-8280-0065)
- Abel Thijs
- Jeske Joanna Katarina van Diemen (ORCID: https://orcid.org/0000-0001-6390-9076)
- Martin den Heijer (ORCID: https://orcid.org/0000-0003-3620-5617)
- Lieve Mees van Zijverden (ORCID: https://orcid.org/0000-0003-3757-0261)
Institutions
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehaf837
- Citations
- 3
- Primary Topic
- LGBTQ Health, Identity, and Policy
- Type
- article
- Field-Weighted Citation Impact
- 7.32